Cargando…

The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress

Blockage of phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signal pathway is effective to increase the cytotoxic effects of oncolytic virus on cancer cells, but the detailed mechanisms are still largely unknown. Based on this, the present study managed to investigate the anti-tumor effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Jinqiong, Wang, Weida, Xiang, Weineng, Jiang, Lin, Zhou, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809975/ https://www.ncbi.nlm.nih.gov/pubmed/34720036 http://dx.doi.org/10.1080/21655979.2021.1999372

Ejemplares similares

Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice
por: Toyama, Shoko, et al.
Publicado: (2010)

ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair
por: Jiao, Wenhui, et al.
Publicado: (2022)

Construction of VSVΔ51M oncolytic virus expressing human interleukin-12
por: Abdulal, Rwaa H., et al.
Publicado: (2023)

Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent
por: Alajez, Nehad M, et al.
Publicado: (2012)

Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy
por: Bishnoi, Suman, et al.
Publicado: (2018)

In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion
por: Wongthida, Phonphimon, et al.
Publicado: (2016)

Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines
por: Namatame, Nachi, et al.
Publicado: (2018)

Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells
por: Bertazza, Loris, et al.
Publicado: (2015)

Enhanced immunosurveillance for animal morbilliviruses using vesicular stomatitis virus (VSV) pseudotypes
por: Logan, Nicola, et al.
Publicado: (2016)

In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells
por: Zhao, Wennan, et al.
Publicado: (2013)

In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells
por: Zhou, Qianxiang, et al.
Publicado: (2016)

Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells
por: Zhou, Qianxiang, et al.
Publicado: (2017)

Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans
por: Poetsch, Joseph H, et al.
Publicado: (2019)

Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

Proteomic analysis of phosphoproteins sensitive to a phosphatidylinositol 3-kinase inhibitor, ZSTK474, by using SELDI-TOF MS
por: Akashi, Tetsuyuki, et al.
Publicado: (2009)

Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474)
por: LIN, LEHANG, et al.
Publicado: (2013)

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
por: Simovic, Boris, et al.
Publicado: (2015)

Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy
por: Muik, Alexander, et al.
Publicado: (2012)

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
por: Hastie, Eric, et al.
Publicado: (2016)

Efficient generation of vesicular stomatitis virus (VSV)-pseudotypes bearing morbilliviral glycoproteins and their use in quantifying virus neutralising antibodies
por: Logan, Nicola, et al.
Publicado: (2016)

Cholesterol supplementation during production increases the infectivity of retroviral and lentiviral vectors pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G)
por: Chen, Yong, et al.
Publicado: (2009)

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer
por: Heiber, Joshua F., et al.
Publicado: (2011)

Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity
por: Bourgeois-Daigneault, Marie-Claude, et al.
Publicado: (2016)

Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
por: Nagalo, Bolni Marius, et al.
Publicado: (2020)

Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells
por: Kim, Teddy E., et al.
Publicado: (2021)

Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474
por: Isoyama, Sho, et al.
Publicado: (2015)

Understanding the Spike Protein in COVID-19 Vaccine in Recombinant Vesicular Stomatitis Virus (rVSV) Using Automated Capillary Western Blots
por: Gillespie, Paul F., et al.
Publicado: (2023)

ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells
por: Wang, Yaochen, et al.
Publicado: (2016)

Experimental Evolution of an Oncolytic Vesicular Stomatitis Virus with Increased Selectivity for p53-Deficient Cells
por: Garijo, Raquel, et al.
Publicado: (2014)

N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells
por: Corredor, Juan C, et al.
Publicado: (2016)

Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”
por: Melzer, Michael Karl, et al.
Publicado: (2017)

Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants
por: Pipperger, Lisa, et al.
Publicado: (2021)

SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

Hydrodynamic characterization of a vesicular stomatitis virus-based oncolytic virus using analytical ultracentrifugation
por: Wawra, Simon, et al.
Publicado: (2023)

Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells
por: Goad, Dakota W., et al.
Publicado: (2023)

Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury
por: Wang, Po, et al.
Publicado: (2016)

First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine
por: Fuchs, JD, et al.
Publicado: (2012)

Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSV(MT)) in golden syrian hamster
por: Ke, Yong, et al.
Publicado: (2023)

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
por: Monath, Thomas P., et al.
Publicado: (2019)

Potent systemic therapy of Multiple Myeloma utilizing Oncolytic Vesicular stomatitis virus coding for Interferon-beta
por: Naik, Shruthi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hvpadu6t1rga4u4397gte81e6j